LinkedIn Profile

Access NovaBiotics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:novabiotics 5264664 May 30th, 2019 12:00AM NovaBiotics Ltd 1.1K 18.00 Open Biotechnology May 30th, 2019 04:10PM May 30th, 2019 04:10PM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. Open biotechnology, biologics, infectious disease, drug discovery & development Open Craibstone Aberdeen GB AB21 9TR NovaBiotics
private:novabiotics 5264664 Feb 17th, 2018 12:00AM NovaBiotics Ltd 649 21.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. NovaBiotics
private:novabiotics 5264664 Feb 16th, 2018 12:00AM NovaBiotics Ltd 649 21.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. NovaBiotics
private:novabiotics 5264664 Feb 15th, 2018 12:00AM NovaBiotics Ltd 649 21.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. NovaBiotics
private:novabiotics 5264664 Feb 14th, 2018 12:00AM NovaBiotics Ltd 649 21.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. NovaBiotics
private:novabiotics 5264664 Feb 13th, 2018 12:00AM NovaBiotics Ltd 649 21.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. NovaBiotics
private:novabiotics 5264664 Feb 12th, 2018 12:00AM NovaBiotics Ltd 649 21.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. NovaBiotics
private:novabiotics 5264664 Feb 11th, 2018 12:00AM NovaBiotics Ltd 649 21.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. NovaBiotics
private:novabiotics 5264664 Feb 10th, 2018 12:00AM NovaBiotics Ltd 649 21.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. NovaBiotics
private:novabiotics 5264664 Feb 9th, 2018 12:00AM NovaBiotics Ltd 649 21.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM NovaBiotics Ltd is a leading, clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals. NovaBiotics is also developing NM001 (Lynovex®), an orphan drug treatment for cystic fibrosis. NM001 has a unique dual antibacterial-mucoactive mode of action that kills bacteria, disables biofilms and disrupts excess mucous produced in the airways of patients with cystic fibrosis (and other chronic respiratory diseases). NM001 is being evaluated in Phase IIa clinical trials as an oral treatment for cystic fibrosis and is also being formulated for inhalation to enable longer term, more targeted delivery of the drug. An exciting pipeline of preclinical stage drug candidates is already demonstrating significant promise. These include NP339 (Novamycin®), an antifungal peptide agent against Candida spp and other clinically relevant yeasts and moulds as well as NP432 (Novarifyn®), a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections. A leading innovator in the anti-infectives space, NovaBiotics has a robust IP portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics is a privately held company, based in Aberdeen, UK and has raised in the order of £12 million in equity investment since its foundation in 2004. NovaBiotics

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.